US: Gilead accused of cutting anti-competitive deals

Combination drug “cocktails” to treat HIV infection are an important part of patients’ routine, allowing them to reduce the number of pills they must take each day. But the lifesaving tablets also were the focus of anti-competitive schemes by the nation’s leading HIV drug manufacturer, Gilead Sciences, according to a consumer lawsuit filed Tuesday.

Gilead forged deals that blocked generic competition, even after Gilead’s brand patents on key medications in the combination pills expired, according to the civil antitrust lawsuit brought in U.S. District Court in San Francisco by HIV/AIDS activists and two service unions.

Combination pills are created using medicines from multiple manufacturers. Gilead’s agreements with those partner companies required that Gilead-brand versions of the HIV-fighting medication tenofovir, which prevents the virus from replicating, would remain in the pills, the lawsuit alleged, even when genericingredients could be used at a fraction of the price.

Full Content: Washington Post

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.

RECOMMENDED FOR YOU
 


More Articles